GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Androgen deprivation therapy for prostate cancer.

CONTEXT Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE To review systematically the evidence on the risk...

An update on androgen deprivation therapy for prostate cancer.

Androgen deprivation therapy (ADT) with gonadal testosterone depletion is the frontline treatment for advanced prostate cancer. Other hormonal interventions have a role in the treatment of prostate cancer. We sought to examine systematically the evidence for hormonal interventions in prostate cancer, risks of ADT, and interventions that mitigate these risks. Search results for therapeutic studi...

Androgen Deprivation for Prostate Cancer

The beneficial effects of androgen deprivation on prostate cancer have been known for more than a half century, based on work demonstrating the androgen dependency of prostate tumor cells. Androgen deprivation therapy (ADT), initially in the form of bilateral orchiectomy, has accordingly long been a mainstay for the palliation of metastatic prostate cancer. For most of its history, concerns abo...